Dopamine D(2) receptors and their role in atypical antipsychotic action: still necessary and may even be sufficient (Q34463410)

2 August 2017

1 reference

title

Dopamine D(2) receptors and their role in atypical antipsychotic action: still necessary and may even be sufficient (English)

1 reference

2 August 2017

1

1 reference

2 August 2017

G Remington

2

1 reference

2 August 2017

language of work or name

English

0 references

publication date

1 December 2001

1 reference

2 August 2017

published in

Biological Psychiatry

1 reference

2 August 2017

volume

50

1 reference

2 August 2017

issue

11

1 reference

2 August 2017

page(s)

873-883

1 reference

Do novel antipsychotics have similar pharmacological characteristics? A review of the evidence

2 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2801%2901251-3

Differentiation of classical and novel antipsychotics using animal models.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2801%2901251-3

Schizophrenia is associated with elevated amphetamine-induced synaptic dopamine concentrations: evidence from a novel positron emission tomography method

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2801%2901251-3

D2-dopamine receptor occupancy measured by IBZM-SPECT in relation to extrapyramidal side effects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2801%2901251-3

Amisulpride has a superior benefit/risk profile to haloperidol in schizophrenia: results of a multicentre, double-blind study (the Amisulpride Study Group).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2801%2901251-3

Treatment-resistant schizophrenic patients respond to clozapine after olanzapine non-response.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2801%2901251-3

Dopamine Receptor Binding Predicts Clinical and Pharmacological Potencies of Antischizophrenic Drugs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2801%2901251-3

The efficacy of drug treatments for dysthymia: a systematic review and meta-analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2801%2901251-3

Special feature: childhood personality characteristics of schizophrenia: manifestations of, or risk factors for, the disorder?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2801%2901251-3

Risperidone in the treatment of first-episode psychotic patients: a double-blind multicenter study. Risperidone Working Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2801%2901251-3

"Schizotaxia": clinical implications and new directions for research

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2801%2901251-3

Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Relation to extrapyramidal side effects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2801%2901251-3

Positron emission tomography studies on D2 and 5-HT2 receptor binding in risperidone-treated schizophrenic patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2801%2901251-3

Central D2-dopamine receptor occupancy in schizophrenic patients treated with antipsychotic drugs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2801%2901251-3

Amisulpride compared with standard neuroleptics in acute exacerbations of schizophrenia: three efficacy studies.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2801%2901251-3

Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2801%2901251-3

Time course of central nervous dopamine-D2 and 5-HT2 receptor blockade and plasma drug concentrations after discontinuation of quetiapine (Seroquel) in patients with schizophrenia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2801%2901251-3

Neuroleptic withdrawal in schizophrenic patients. A review of the literature

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2801%2901251-3

Dopamine-cell depolarization block as a model for the therapeutic actions of antipsychotic drugs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2801%2901251-3

Receptor binding of N-(methyl-11C) clozapine in the brain of rhesus monkey studied by positron emission tomography (PET).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2801%2901251-3

7 January 2021

The history of clozapine

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2801%2901251-3

Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2801%2901251-3

Atypical antipsychotics: new directions and new challenges in the treatment of schizophrenia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2801%2901251-3

Increased dopamine d(2) receptor occupancy and elevated prolactin level associated with addition of haloperidol to clozapine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2801%2901251-3

Does fast dissociation from the dopamine d(2) receptor explain the action of atypical antipsychotics?: A new hypothesis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2801%2901251-3

Relationship between dopamine D(2) occupancy, clinical response, and side effects: a double-blind PET study of first-episode schizophrenia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2801%2901251-3

A positron emission tomography study of quetiapine in schizophrenia: a preliminary finding of an antipsychotic effect with only transiently high dopamine D2 receptor occupancy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2801%2901251-3

5-HT2 and D2 receptor occupancy of olanzapine in schizophrenia: a PET investigation.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2801%2901251-3

PET evidence that loxapine is an equipotent blocker of 5-HT2 and D2 receptors: implications for the therapeutics of schizophrenia.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2801%2901251-3

Increased dopamine transmission in schizophrenia: relationship to illness phases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2801%2901251-3

Single photon emission computerized tomography imaging of amphetamine-induced dopamine release in drug-free schizophrenic subjects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2801%2901251-3

Dopamine D2 receptor occupancy by olanzapine or risperidone in young patients with schizophrenia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2801%2901251-3

Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo. A meta-analysis of randomized controlled trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2801%2901251-3

Increased dopamine synthesis rate in medial prefrontal cortex and striatum in schizophrenia indicated by L-(beta-11C) DOPA and PET.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2801%2901251-3

Amisulpride versus placebo in the medium-term treatment of the negative symptoms of schizophrenia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2801%2901251-3

In vivo characteristics of dopamine D2 receptor occupancy by amisulpride in schizophrenia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2801%2901251-3

Schizotaxia, schizotypy, schizophrenia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2801%2901251-3

7 January 2021

Schizotaxia revisited

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2801%2901251-3

The role of serotonin in antipsychotic drug action

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2801%2901251-3

Major psychosis and dopamine: controversial features and some suggestions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2801%2901251-3

Hyperactivity of associations in psychosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2801%2901251-3

D1, D2, and 5-HT2 receptor occupancy in relation to clozapine serum concentration: a PET study of schizophrenic patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2801%2901251-3

Central D2-dopamine receptor occupancy in relation to antipsychotic drug effects: a double-blind PET study of schizophrenic patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2801%2901251-3

Positron emission tomography finding of a high striatal D2 receptor occupancy in olanzapine-treated patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2801%2901251-3

A PET study of 5-HT2 and D2 dopamine receptor occupancy induced by olanzapine in healthy subjects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2801%2901251-3

Glutamate receptor dysfunction and schizophrenia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2801%2901251-3

Improvement of some schizophrenic deficit symptoms with low doses of amisulpride

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2801%2901251-3

Amisulpride vs. risperidone in the treatment of acute exacerbations of schizophrenia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2801%2901251-3

Children's Self-Reported Psychotic Symptoms and Adult Schizophreniform Disorder

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2801%2901251-3

Amisulpride, and atypical antipsychotic, in the treatment of acute episodes of schizophrenia: a dose-ranging study vs. haloperidol. The Amisulpride Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2801%2901251-3

Cognitive and behavioural functioning in men with schizophrenia both before and shortly after first admission to hospital. Cross-sectional analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2801%2901251-3

In vivo olanzapine occupancy of muscarinic acetylcholine receptors in patients with schizophrenia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2801%2901251-3

Elevated dopa decarboxylase activity in living brain of patients with psychosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2801%2901251-3

Impact of clozapine on negative symptoms and on the deficit syndrome in refractory schizophrenia. Department of Veterans Affairs Cooperative Study Group on Clozapine in Refractory Schizophrenia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2801%2901251-3

D2-dopamine receptor occupancy differs between patients with and without extrapyramidal side effects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2801%2901251-3

Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2801%2901251-3

Brain receptors for antipsychotic drugs and dopamine: direct binding assays

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2801%2901251-3

Dopamine D4 receptors elevated in schizophrenia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2801%2901251-3

Antipsychotic Drugs: Direct Correlation Between Clinical Potency and Presynaptic Action on Dopamine Neurons

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2801%2901251-3

Antipsychotic drugs which elicit little or no parkinsonism bind more loosely than dopamine to brain D2 receptors, yet occupy high levels of these receptors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2801%2901251-3

Rapid release of antipsychotic drugs from dopamine D2 receptors: an explanation for low receptor occupancy and early clinical relapse upon withdrawal of clozapine or quetiapine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2801%2901251-3

Sulpiride augmentation in people with schizophrenia partially responsive to clozapine. A double-blind, placebo-controlled study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2801%2901251-3

Quetiapine in patients with schizophrenia. A high- and low-dose double-blind comparison with placebo. Seroquel Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2801%2901251-3

One-year, low-dose neuroleptic study of in-patients with chronic schizophrenia characterised by persistent negative symptoms. Amisulpride v. haloperidol

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2801%2901251-3

Mode of action of atypical neuroleptics in relation to the phencyclidine model of schizophrenia: role of 5-HT2 receptor and alpha 1-adrenoceptor antagonism [corrected]

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2801%2901251-3

Binding of antipsychotic drugs to cortical 5-HT2A receptors: a PET study of chlorpromazine, clozapine, and amisulpride in schizophrenic patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2801%2901251-3

Toward reformulating the diagnosis of schizophrenia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2801%2901251-3

Cloning of the gene for a human dopamine D4 receptor with high affinity for the antipsychotic clozapine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2801%2901251-3

Clozapine versus typical neuroleptic medication for schizophrenia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2801%2901251-3

Childhood precursors of schizophrenia: facial expressions of emotion.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2801%2901251-3

Dopamine blockade and clinical response: evidence for two biological subgroups of schizophrenia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2801%2901251-3

The in vivo effects of olanzapine and other antipsychotic agents on receptor occupancy and antagonism of dopamine D1, D2, D3, 5HT2A and muscarinic receptors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2801%2901251-3

Controlled, dose-response study of sertindole and haloperidol in the treatment of schizophrenia. Sertindole Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2801%2901251-3

Overcoming the neuroleptic-induced deficit syndrome: clinical observations with remoxipride

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2801%2901251-3

Safety profile of amisulpride in short- and long-term use.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2801%2901251-3

10.1016/S0006-3223(01)01251-3

7 January 2021

Identifiers

DOI

1 reference

2 August 2017

1 reference